NCT07704892 Efimosfermin alfa Metabolic Dysfunction Associated Steatohepatitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07704892—A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) (NEBULA-2)—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07704892 is a hot trial to watch

Metabolic Dysfunction Associated Steatohepatitis is increasingly segmented by mechanism, biomarker, line of therapy, geography and endpoint architecture. NCT07704892 is notable because it tests Efimosfermin alfa in a Phase 3 design while Part A: Proportion of participants achieving improvement in liver fibrosis by >=1 stage and no worsening of MASH serves as the main decision variable. The value of this program will depend on whether the protocol converts biological rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add mechanism, development-status and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The design should be read as an evidence architecture, not just a phase label. Allocation is Randomized, masking is Triple, and the intervention model is Parallel Assignment. Enrollment of 380 participants across the reported study geography shapes statistical precision, execution risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.

• Primary: Part A: Proportion of participants achieving improvement in liver fibrosis by >=1 stage and no worsening of MASH — At Week 96
• Secondary: Part A: Proportion of participants achieving change from Baseline in vibration-controlled transient elastography (VCTE)- liver stiffness measurement (LSM) and in enhanced liver fibrosis (ELF) score — Baseline (Day 1) and Week 96
• Secondary: Part A Change from Baseline in VCTE-LSM — Baseline (Day 1) and Week 96
• Secondary: Part A: Proportion of participants with Treatment-Emergent Adverse Events (TEAEs) and TEAEs by severity — Week 96
• Secondary: Part A: Proportion of participants with TEAEs leading to discontinuation and TEAEs leading to discontinuation by severity — Week 96

Benchmark readouts in the surrounding field

• A Randomized, Double-blind, Placebo-controlled Parallel Group Phase 2a Study to Evaluate the Efficacy and Safety of HPG1860 in Subjects With Nonalcoholic Steatohepatitis (Phase 2): Safety and Tolerability of Treatment = 12 Participants ; Safety and Tolerability of Treatment = 13 Participants
• Vitamin E Dosing Study (VEDS): A Dose Finding Study of Vitamin E for the Treatment of Adult NAFLD (Phase 2): Relative Change in Alanine Aminotransferase (ALT) From Baseline to 24 Weeks(Mean) = -12.2 % change (Standard Deviation, 33.4); Relative Change in Alanine Aminotransferase (ALT) From Baseline to 24 Weeks(Mean): P-Value = <0.0001; P-Value = <0.0001; P-Value = 0.001
• Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial (Phase 2): AE(gastrointestinal events) = Most frequent adverse events were gastrointestinal events, which were transient and occurred within the first few weeks of treatment. ; AE(gastrointestinal events) = Most frequent adverse events were gastrointestinal events, which were transient and occurred within the first few weeks of treatment.

These indexed results are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, treatment line, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.

Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Efimosfermin alfa (Phase 3; FGF21R)

Company & Deal Intelligence context: GSK Plc — http://www.gsk.com

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes that connect activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.

Bottom line

NCT07704892 is a focused lens on Metabolic Dysfunction Associated Steatohepatitis development. Its value will be determined by whether Efimosfermin alfa can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from existing benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.